789

CALY-002, AN ANTI-IL-15 ANTIBODY, PREVENTS GLUTEN CHALLENGE-INDUCED MUCOSAL DAMAGE AND INFLAMMATION: RESULTS FROM A PHASE 1A/B STUDY

Date
May 20, 2024

Introduction
Interleukin-15 (IL-15) is a cytokine involved in tissue homeostasis and inflammation, and a potent regulator of innate and adaptive immune responses. IL-15 expression has been shown to be dysregulated in celiac disease (CeD). Preclinical translational studies in humans and animal models have suggested therapeutic potential for blocking IL-15 in CeD. CALY-002 is an investigational therapeutic monoclonal antibody that neutralizes with equally high potency free and IL-15Ra-complexed IL-15.
Methodology
A Phase 1a/b study (NCT04593251) evaluated double blind, placebo-controlled intravenous administration (IV) of CALY-002 in single ascending doses (SAD) in healthy volunteers and multiple ascending doses (MAD) in patients with well-controlled CeD challenged with 3g/day gluten during the 8-week treatment period, while maintaining their gluten-free diet (GFD). Each of the three MAD cohorts (70 mg, 210 mg, 700 mg) was planned for 6 patients receiving CALY-002 and 3 receiving placebo for 8 weeks, i.e. 4 IV doses, each 2 weeks apart.
Objectives of the study were evaluation of safety, pharmacokinetics (PK), immunogenicity, and exploratory efficacy. Safety of CALY-002 was assessed by recording adverse events (AE), hematology and biochemistry lab testing, ECG, and vital signs. Exploratory efficacy endpoints included villous height-crypt depth ratio (VH:CD) and intra-epithelial lymphocyte density per 100 villous enterocytes (IEL) assessed in endoscopic duodenal biopsies during screening and at the end of the 8-week treatment and concomitant gluten challenge. Inclusion was restricted to those patients who had initially a histologically largely unaffected mucosa under GFD as reflected in a VH:CD >1.5 and IEL <40.
Results
Evaluation of the safety results of the 34 randomized and dosed patients shows good tolerability and no safety signals. Histologically evaluable patients included those who had received all 4 doses, undergone both endoscopies and been compliant with the gluten challenge for the 8-week treatment period. The change from baseline (CFB) VH:CD results of the pooled placebo-treated patients and of the CALY-002-treated cohort patients is shown in Figure 1A, while Figure 1B shows CFB for IEL. Patients who had received placebo show the expected decrease from baseline in VH:CD (mean CFB -0.69) and increase in IEL (mean CFB +15) validating the study design and conduct. Patients who had received CALY-002 demonstrate a marked numerically reduced deterioration of VH:CD and IEL, especially at the 700mg dose (mean CFB VH:CD -0.28 and mean CFB IEL +2).
Conclusion
This Phase 1a/b trial is the first to demonstrate that blocking IL-15 using a potent antibody can attenuate mucosal injury induced by gluten challenge in well-controlled CeD patients. These encouraging results warrant further investigations of CALY-002 in CeD.

Tracks

Related Products

Thumbnail for INTERIM RESULTS FROM A FIRST-IN-HUMAN STUDY OF THE ANTI-IL-15 ANTIBODY CALY-002 FOR TREATING CELIAC DISEASE AND EOSINOPHILIC ESOPHAGITIS
INTERIM RESULTS FROM A FIRST-IN-HUMAN STUDY OF THE ANTI-IL-15 ANTIBODY CALY-002 FOR TREATING CELIAC DISEASE AND EOSINOPHILIC ESOPHAGITIS
INTRODUCTION Interleukin-15 (IL-15) is an important cytokine involved in tissue homeostasis and inflammation, and a potent regulator of innate and adaptive immune responses…
Thumbnail for NAVIGATING THE MAZE OF FUNCTIONAL DYSPEPSIA: EMERGENCE OF A NEW ENTITY, POSTPRANDIAL EPIGASTRIC PAIN
NAVIGATING THE MAZE OF FUNCTIONAL DYSPEPSIA: EMERGENCE OF A NEW ENTITY, POSTPRANDIAL EPIGASTRIC PAIN
BACKGROUND: Historically, functional dyspepsia (FD) has been subdivided into postprandial distress syndrome, PDS, with meal-related symptoms (i.e. early satiation or postprandial fullness) and epigastric pain syndrome, EPS, defined as meal-unrelated (i.e…
Thumbnail for ACUTE MUCOSAL REACTIONS FOLLOWING FOOD ADMINISTRATION IN IRRITABLE BOWEL SYNDROME ARE NOT ASSOCIATED WITH ALTERED PERMEABILITY OR MAST CELL ACTIVATION EX VIVO
ACUTE MUCOSAL REACTIONS FOLLOWING FOOD ADMINISTRATION IN IRRITABLE BOWEL SYNDROME ARE NOT ASSOCIATED WITH ALTERED PERMEABILITY OR MAST CELL ACTIVATION EX VIVO
INTRODUCTION: Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction characterized by abdominal pain associated with bowel movements. Local allergic reactions have been implicated as a mechanism underlying the food-related symptoms often reported by IBS patients…
Thumbnail for DUODENAL T CELL PROFILE PREDICTS RESPONSE TO HIGH-DOSE PROTON PUMP INHIBITORS IN FUNCTIONAL DYSPEPSIA
DUODENAL T CELL PROFILE PREDICTS RESPONSE TO HIGH-DOSE PROTON PUMP INHIBITORS IN FUNCTIONAL DYSPEPSIA
I: Functional dyspepsia (FD) is a chronic gastrointestinal (GI) disorder with incompletely understood pathophysiology…